TRANSFORM 1
TRANSFORM-1: Phase III Trial of Navitoclax + Ruxolitinib vs Placebo + Ruxolitinib in Previously Untreated Myelofibrosis

Released: December 12, 2023

Activity

Progress
1
Course Completed